Ankara City Hospital Bilkent

saglik.gov.tr

Total trials

397

Active

91

Phase 3

1

Total enrollment

57,745

Read this sponsor's pipeline like an analyst.

Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.

~15-30 sec · cached for 24h

Pipeline matrix

Showing 17 of 17 active programs · click any cell for trials

InterventionEarly Phase 1Phase 1Phase 2Phase 3Phase 4N/ATotal
Umbilical Cord-Derived Mesenchymal Stem Cells1
Umblical Cord-Derived Mesenchymal Stem Cell-Derived Exosomes1
Control group1
Lidocaine and Dexamethasone for PENG Block1
5% dextrose1
Ephedrine1
Noradrenalin1
Lidocaine spray1
Rocuronium1
Etofenamat1
Diclofenac1
Dutasteride1
Bupivacain1
moderate dose Dexamethasone1
High dose dexamethasone1
Lidocaine1
Normal Saline1

Next readouts

  • 2023-07-01
  • 2024-05-01
  • 2024-09-20
  • 2024-10-01
  • 2024-12-01
  • 2026-04-01
  • 2026-04-23
  • 2026-07-30
  • 2026-10-01
  • 2026-10-01

Top conditions

  • Anesthesia18
  • Postoperative Pain10
  • Sedation7
  • Pain, Postoperative6
  • Knee Osteoarthritis5
  • Regional Anesthesia5
  • Cardiac Surgery5
  • Analgesia5

Frequently asked questions about Ankara City Hospital Bilkent

How many clinical trials does Ankara City Hospital Bilkent have on ClinicalTrials.gov?
Ankara City Hospital Bilkent is listed as the lead sponsor on 397 clinical trials in ClinicalTrials.gov, 91 of which are currently active (recruiting, enrolling, or ongoing).
How many of Ankara City Hospital Bilkent's trials are in Phase 3?
1 of Ankara City Hospital Bilkent's trials are in Phase 3, spread across 17 active drug programs.
What therapeutic areas does Ankara City Hospital Bilkent focus on?
Ankara City Hospital Bilkent's most-studied conditions on ClinicalTrials.gov are Anesthesia, Postoperative Pain, Sedation, Pain, Postoperative, Knee Osteoarthritis.
When are Ankara City Hospital Bilkent's next clinical trial readouts?
Ankara City Hospital Bilkent has 10 upcoming primary-completion readouts tracked here; the soonest is “Lidocaine Spray Use on Patients Comfort in Undergoing Bladder Catheterization”, expected around 2023-07-01.